No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Devices
Founded in 1979 and headquartered in Marlborough, Massachusetts, Boston Scientific Corporation is a global leader in designing, manufacturing, and marketing advanced medical devices. The company's products cater to a wide range of interventional medical specialties worldwide, organized primarily under its MedSurg and Cardiovascular segments. The MedSurg division focuses on technologies for diagnosing and treating gastrointestinal, pulmonary, urological, and pelvic conditions. Within the expansive Cardiovascular segment, Boston Scientific provides solutions for cardiac rhythm management, including implantable defibrillators, pacemakers (both standard and cardiac resynchronization therapy models), and remote patient monitoring systems. It also offers sophisticated tools for addressing heart rate and rhythm disorders, such as 3-D cardiac mapping, ablation, diagnostic, and intracardiac ultrasound catheters, alongside necessary accessories. Furthermore, the company's portfolio extends to neuromodulation, featuring spinal cord stimulators for chronic pain, indirect decompression systems, and deep brain stimulation systems. Its interventional cardiology products are crucial in treating coronary artery disease and aortic valve conditions. Lastly, Boston Scientific is a key provider of devices for arterial and venous diseases and cancer therapies, encompassing stents, balloon catheters, guidewires, atherectomy and thrombectomy systems, peripheral embolization tools, radioactive microspheres, cryotherapy ablation systems, and various micro and drainage catheters.
www.bostonscientific.comNo one on the platform currently holds BSX.F.
No tracked institution reports a position in BSX.F as of their last filing.
No one on the platform has traded BSX.F yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Analyst estimates unavailable for this ticker.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-29 | $0.73 | $0.75 | +2.9% |
| 2026-04-22 | $0.68 | $0.69 | +1.5% |
| 2026-02-04 | $0.67 | $0.68 | +2.4% |
| 2025-10-22 | $0.61 | $0.64 | +5.1% |
| 2025-07-23 | $0.62 | $0.64 | +3.4% |
| 2025-04-23 | $0.62 | $0.69 | +11.4% |
| 2025-02-05 | $0.64 | $0.68 | +6.5% |
| 2024-10-23 | $0.53 | $0.57 | +7.2% |